Maduck Sean sold $2.3M of CORT
Maduck Sean (See Remarks) sold 20,305 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.70 ($2.33M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the disclosed open-market sale size, price, and post-transaction holdings. This typically informs sentiment but rarely changes fundamentals.
Market read
Traders may briefly reassess sentiment around CORT due to insider selling, but the 10b5-1 structure makes it less likely to drive a sustained repricing.
What to watch
The article does not provide broader insider activity history, total insider ownership changes over time, or whether other executives sold/bought around the same period.
Background
The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported by an officer and explicitly tied to a pre-arranged 10b5-1 plan.
Ticker impact
Corcept Therapeutics Form 4 shows officer Maduck Sean sold 20,305 shares at $114.7045 on 2026-08-03 under a 10b5-1 plan.
Limited near-term impact; any reaction is likely muted because the sale is pre-arranged under Rule 10b5-1.
The filing is a primary-source Form 4 with a specified sale price, size, and explicit 10b5-1 pre-arrangement, which typically reduces interpretive signal versus discretionary selling.
Market effects
No clear sector read-through from a single routine 10b5-1 sale.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can still coincide with private views on valuation or liquidity needs, so some traders may treat it as a mild negative signal.
Key entities
- issuerCorcept Therapeutics Inc
Subject of the Form 4 insider transaction disclosure (CORT).
- insiderMaduck Sean
Officer who sold 20,305 shares under a Rule 10b5-1 plan.
